Joe Duarte

Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert.  He has been a professional investor and independent analyst since 1990.  He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.  

Analyst Articles

Shares of Medidata Solutions, Inc. (MDSO) headed higher this morning on a very robust beat of revenues and earnings for its first quarter.  Revenues came in at $104.2 million vs. an expected $103.4 million.  Adjusted earnings came in at 25 cents per share vs. an expected 19 cents per share. The… Read More

The times are clearly changing, both in the markets and in our focus. It’s a big world and there are a lot of companies out there who do special things. Read More

The Nasdaq Biotech Index (NBI) rallied an impressive 5.95% on April 5th.  The conventional wisdom thrown around Wall Street was that the rally came after the U.S. Treasury passed a new set of rules to prevent any more U.S. drug companies from merging with foreign companies in order to pay… Read More

The Nasdaq Biotech Index (NBI) rallied an impressive 5.95% on April 5th.  The conventional wisdom thrown around Wall Street was that the rally came after the U.S. Treasury passed a new set of rules to prevent any more U.S. drug companies from merging with foreign companies in order to pay… Read More

This morning shares of Opko Health (OPK) fell hard in pre-market trading. The company received an FDA notice that it will not receive approval for its drug, Rayaldee.  What’s important here is that the denial was not directly related to Opko, but to the company that will manufacture the drug. … Read More

This morning shares of Opko Health (OPK) fell hard in pre-market trading. The company received an FDA notice that it will not receive approval for its drug, Rayaldee.  What’s important here is that the denial was not directly related to Opko, but to the company that will manufacture the drug. … Read More

We think the market is wrong about Opko Health (OPK). It’s acquisitions have already delivered profits and operating capital, buying it now could be an excellent long-term play. We are also looking to add this company to our EBIS list in the not too distant future.Opko’s strategy of consolidating its recent acquisitions resulted… Read More

We think the market is wrong about Opko Health (OPK). It’s acquisitions have already delivered profits and operating capital, buying it now could be an excellent long-term play. We are also looking to add this company to our EBIS list in the not too distant future.Opko’s strategy of consolidating its recent acquisitions resulted… Read More